Point-of-Care (POC) Infectious Disease Diagnostics Market: Competitive Intelligence and Tracking Report 2018 – 2026

Point-of-Care (POC) Infectious Disease Diagnostics
Market Shows Expected Growth from 2018-2026
Point-of-Care (POC) Infectious Disease Diagnostics Market, by Technology
(Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), By
Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease,
Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health
Disorders, and Others), By End User (Hospitals, Diagnostic Laboratories, HomeCare Settings, and Others), and Region - Global Industry Insights, and Forecast
till 2025
The Global Point-of-Care (POC) Infectious Disease Diagnostics Market was valued at US$ 1,764.6
million in 2016 and is expected to witness a robust CAGR of 14.5% over the forecast period (2017 –
Emerging economies such as Africa (West Africa), India, Brazil, and China have limited centralized
laboratory facilities. In emerging economies point of care diagnostic is needed due to unavailability of
labs, infrastructure, associated costs, and trained personnel. Most of the point-of-care diagnostic tests
are comparatively easy to perform and can be performed with minimum amount of training. Infectious
diseases such as HIV, Malaria, Tuberculosis, and others are highly prevalent in these emerging
economies wherein point-of-care testing is a necessity. Furthermore, disease outbreaks are very
frequent in these regions such as Yellow Fever disease outbreak in Nigeria and Brazil in December and
November 2017, respectively and Acute Hepatitis E disease outbreak in Nigeria in July 2017, wherein
point of care diagnostics could be helpful.
Market Dynamics
Technological advancements (innovative assays) to facilitate speedy diagnosis and extensive product
portfolios of point of care infectious disease diagnostics offered by manufacturer’s supports the growth
of Point of Care Infectious Disease Diagnostics Market. Development of innovative point-of-care
diagnostics for infectious diseases, wide applications in remote locations, constant disease outbreaks,
and government funding for product development and research is expected to fuel growth of the
market. The market is expected to gain significant growth, owing to increasing adoption of point-ofcare diagnostics for infectious disease in remote locations, volume driven growth, and rising prevalence
of infectious diseases such as HIV.
Ask For Sample Copy Of This Business Research Report :
Initiatives and funding from individual organizations for point-of-care infectious disease
diagnostics is expected to boost the market growth over the forecast period
Various organizations and governments are focused on research and development for infectious
diseases to provide effective diagnostic and treatment options. For instance, QuantuMDx Group
received funding from Bill & Melinda Gates Foundation to develop and test company’s CAPTURE-XT
pathogen concentration technology and Q-POC molecular diagnostic platform for rapid low cost
detection of tuberculosis in 2016. In January 2018, University of Glasgow-led project received US$
1.85 million funding, which is a part of Global Challenges Research Fund (GCRF). This project will
develop new tests for parasitic diseases and point-of-care testing in remote locations to help enable
rapid diagnosis, and rapid treatment.
However, limitations associated with point-of-care testing such as specific steps and timing and
different methodologies than laboratory testing, which may provide difference in the test results from
laboratory testing may hinder the growth of the market. Moreover, in remote locations proper inventory
system must be planned before to prevent deterioration, lack of stock, and shelf life issues which may
further hinder growth of the market.
Major players operating in the point of care infectious disease diagnostics market include Danaher
Corporation, Abbott Laboratories, Alcon Laboratories, Inc., Hoffman-La Roche Ltd., Becton,
Dickinson, and Company, Trinity Biotech Plc, AccuBioTech Co., Ltd. and Cardinal Health, Inc.
Detailed Segmentation:
•Global Point of Care Infectious Disease Diagnostics Market, By Technology:
•Lateral Flow
•Agglutination Assays
•Solid Phase
•Global Point of Care Infectious Disease Diagnostics Market, By Application:
•Tropical Disease
•Liver Disease
•Inflammatory Disease
•Respiratory Disease
•Hospital Associated Infections (HAIs)
•Sexual Health Disorders
Advances in technology of point of care diagnostics is expected to support the growth of the point
of care infectious disease diagnostics market
Centralized laboratory testing is the gold standard and has established in biochemistry, hematology, and
diagnostics. Point-of-care diagnostic offers various advantages such as ease of use in remote areas,
technological advancements, and lowered price points. Small handheld point-of-care devices are
portable and can be used by patients themselves. These tests use fingerstick or capillary samples, which
are directly applied to instrument and avoid need of sample containers. Technologies such as lateral
flow, various molecular assays integrated with point-of-care have changed the outlook of point-of-care
diagnostics. For instance, products offered by leading manufacturers such as Alere and Roche are
immunoassays, which are cost-effective and provide rapid results. Furthermore, in 2014, Becton,
Dickinson, and Company offered point-of-care system BD FACSPresto for HIV/AIDS.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

The Global Point-of-Care (POC) Infectious Disease Diagnostics Market was valued at US$ 1,764.6 million in 2016 and is expected to witness a robust CAGR of 14.5% over the forecast period (2017 – 2025).